Allogene reports Q3 net loss $61.3M; cash $497.7M; ALPHA2 on track

Allogene Therapeutics, Inc.

2023-Q3 EPS reported -$1.55 revenue$139,000

Net loss of $61.3M ($0.37/sh) for Q3 2023; R&D expense $46.0M, G&A $17.0M.
Cash, equivalents and investments $497.7M as of Sept 30, 2023; runway into 2H 2025.
2023 guidance: cash use ~$230M; GAAP op. expense ~$340M incl. ~$80M stock comp.
ALPHA2 Phase 2 trial for ALLO-501A in LBCL enrolling; completion expected 1H 2024, data by end 2024.
New CFO Geoffrey Parker and General Counsel Earl Douglas appointed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Allogene Therapeutics, Inc. reported financial results for for the quarter ended September 30, 2023.

Period: for the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.